APA House Call: Treating Disassociation Issues for Trauma Patients

Article

David Jiang, MD, explains some preffered therapies and medications for trauma patients.

The 2020 American Psychiatric Association (APA) Annual Meeting was cancelled this year, with plans made to convert the world-leading psychiatry conference into a two-part virtual session and educational platform for attendees.

In lieu of regular on-site coverage, HCPLive® will be running a series of interviews, insights, and reporting on topics that frequently headline the APA meeting—featuring familiar experts.

For patients who are suffering from PTSD or trauma, comorbidities like depression and anxiety are expected.

This combination of comorbid psychiatric conditions can result in a number of negative symptoms, such as dissociation, which can be particularly difficult to treat.

While there are a number of different causes for trauma, such as military combat, childhood abuse, and traumatic experiences, dissociation can be a common symptom.

However, each patient with different sets of circumstances should be treated differently.

In an interview with HCPLive®, David H. Jiang, MD, an assistant professor of psychiatry at Mount Sinai Morningside, explained some of the potential non-pharmacological options to help this patient population, as well as some of the medications that he has had success with.

Despite the cancellation of the live version of the conference, Jiang will be presenting during the APA: On Demand virtual meeting. Jiang’s presentation centers around the award-winning film, You Were Never Really Here, a story about an individual’s journey dealing with both childhood and combat trauma.

The short film will lead into a discussion on how new approaches could improve trauma screening in a diverse mental healthcare setting.

Recent Videos
Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X | Image Credit: Sierra Eye Associates
Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas
Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD | Image Credit: Austin Retina Associates
Dilsher Dhoot, MD: OTX-TKI for NPDR in Interim Phase 1 HELIOS Results  | Image Credit: LinkedIn
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
Veeral Sheth, MD: Assessment of EYP-1901 Supplemental Injection Use in Wet AMD | Image Credit: University Retina
© 2024 MJH Life Sciences

All rights reserved.